HEPATOLOGY 润色咨询

HEPATOLOGY

出版年份:1981 年文章数:5641 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:4.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2022-04-14 ms4000000877142304

    课题组的第二篇hepatology接收了。
    贡献一个timeline;
    11-nov-2021~21-dec-2021 reject with opportunity to resubmit
    8-apr-2022 修回,当天主编直接 accept
    总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。

    10

    展开10条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2021-10-16 心内一科

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向:临床转化;基础医学
    经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!

    5

    展开5条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2020-06-24 1484bf18m20暂无昵称

    中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2023-06-20 1ddf3775m09(暂无匿称) 来自上海

    Submission Received状态一般会持续几天?

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2023-05-13 川云不息 来自浙江省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:临床转化;免疫;肝癌
    经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2022-10-30 wfkevinhan

    偏重的研究方向:侵袭转移机制;肝癌
    经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2021-02-19 ms6000001798901952

    三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021)

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2022-08-26 alkfhaf

    有没有最近投稿的小伙伴呀,交流一下

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2021-11-23 骨科小www

    怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061123, encodeId=5b501061123fb, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向:临床转化;基础医学<br>经验分享:肝病领域的权威杂志,可惜被国内某李姓长江玩坏了。整天在上面卖NASH和肝I/R损伤的文章,净整些NF-kb、ASK1/P38和GSK-3b通路,一个流水线出的假文章!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:38:56 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799571, encodeId=d128e9957138, content=中了一篇letter,6月17日下午submit,6月18日accept with editor's comments,实际没修改什么内容,编辑让追改了格式。6月19日天按编辑要求返回,遇到周六周天没审,6月22日正式ACCEPT。啥时候能中article就好了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Wed Jun 24 16:07:52 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925381, encodeId=fb4592538117, content=三年的工作终于以Original Article 发表了。总体来说editors和reviewers的水平很专业,比较强调临床的重要意义, 机制方面要求完整性,是消化领域非常优秀的期刊。 Submission completed (28-Jun-2020) Reject with opportunity to resubmit (26-Jul-2020) Revision 1 Submission Completed (21-Jan-2021) Accept with Revisions (11-Feb-2021) Revision 2 submission completed (15-Feb-2021) ACCEPT (18-Feb-2021) , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=238, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7f765429324, createdName=ms6000001798901952, createdTime=Fri Feb 19 03:15:48 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241121, encodeId=7f3c12411213b, content=有没有最近投稿的小伙伴呀,交流一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62321965538, createdName=alkfhaf, createdTime=Fri Aug 26 10:50:41 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073276, encodeId=478410e3276e6, content=怎么好多mapk ask nfkb 泛素化一套的文章,作图风格以及套路一看就是一个实验室出来的......, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/16/4324cfc7a25cfb745d30ee6ba4bbddb9.jpg, createdBy=32842126143, createdName=骨科小www, createdTime=Tue Nov 23 19:58:52 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2020-05-14 xrkguoguo

    想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。

    2

    展开2条回复
共150条页码: 1/15页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分